How Progestins in HRT Impact Risk of Breast Cancer

EmaxHealth

Submitted by Deborah Mitchell on 2010-08-11

The risk of breast cancer associated with the use of synthetic progesterone known as progestins has been a topic of much controversy and concern for many years. Now a new study reports on the impact of progestins on breast cancer in animals models.

Impact of Progestins

In 2002, the large, well-known Women’s Health Initiative (WHI) Estrogen plus Progestin Study was stopped because the investigators found an increased risk of breast cancer and cardiovascular disease in women who were taking the active pills (that included progestins) compared with women taking placebo.

A subsequent study (2008) found that estrogen plus progestin HRT increased the risk that women will have abnormal mammograms and breast biopsies. Then in 2009, a new study of WHI participants found that women who stopped taking the estrogen plus progestin had a significant decline in breast cancer risk.

Progestin Study
Now researchers at the University of Missouri have compared four types of progestins used in HRT and discovered found four distinctly different outcomes on the progression of breast cancer. The four synthetic progestins used included medroxporgresterone acetate (MPA), norgesterel (N-EL), norethindrone (N-ONE), and megestrol acetate (MGA).

MORE…

PG

Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.